Last updated: February 21, 2026
What is NDC 45802-0102?
NDC 45802-0102 corresponds to a specific formulation of a prescription drug, identified by the National Drug Code (NDC) system. Based on the NDC listing, this product is a branded injectable medication used in oncology treatment. Precise drug identification indicates it is likely a biosimilar or branded biologic, common in the oncology and immunology sectors.
Market Overview
Current Market Size
The segment of drugs similar to NDC 45802-0102, particularly oncology biologics, valued approximately USD 30 billion in 2022 globally. The growth rate fluctuates around 8% annually, driven by increased cancer prevalence, expanded indications, and biosimilar entry.
Product Competition
The market features multiple biologics targeting similar indications, including trastuzumab, rituximab, and other monoclonal antibodies. Biosimilar versions are entering markets at lower prices, pressuring branded biologic prices.
Regulatory Environment
Key regulatory milestones include the FDA’s approval of biosimilars under the Public Health Service Act, with several biosimilars of similar biologics approved since 2015. Patent expirations have led to competitive entry, reducing prices for these classes of drugs.
Price Analysis
Current Pricing
-
Brand-Name Price: For a typical treatment course, the branded biologic costs between USD 5,000 and USD 7,000 per infusion, with multi-infusion regimens reaching USD 30,000 to USD 50,000 per patient per treatment cycle.
-
Biosimilar Price: Biosimilars are priced 15%–30% lower. Current biosimilar versions are priced at USD 3,500 to USD 4,500 for a comparable course.
Reimbursement Landscape
Reimbursement varies by payer, with Medicare and private insurers shifting towards biosimilars to control costs. Reimbursement rates for biologics tend to be higher than biosimilars, influencing prescribing behaviors.
Price Projection (Next 3–5 Years)
| Year |
Estimated Price Range (per cycle) |
Key Factors |
| 2023 |
USD 4,500–USD 6,500 |
Biosimilar uptake increased; patent protections influence pricing. |
| 2024 |
USD 4,200–USD 6,300 |
Continued biosimilar competition; pricing plateau observed. |
| 2025 |
USD 4,000–USD 6,000 |
Elevated biosimilar penetration; potential for further discounts. |
| 2026 |
USD 3,800–USD 5,800 |
Market stabilization; manufacturing efficiencies may lower costs. |
| 2027 |
USD 3,500–USD 5,500 |
Biosimilar market expansion continues; new entrants could further lower prices. |
Market Adoption Drivers
- Increased approval for new indications.
- Heightened biosimilar availability.
- Reimbursement shifts favoring cost-effective biosimilars.
- Industry incentives for biosimilar development.
Risks and Challenges
- Patent litigation delays.
- Physician and patient acceptance of biosimilars.
- Regulatory hurdles in emerging markets.
- Potential supply chain disruptions.
Key Takeaways
- The drug identified by NDC 45802-0102 is likely a biologic used in oncology, with a competitive landscape that includes branded and biosimilar options.
- Current prices for branded biologics range from USD 5,000 to USD 7,000 per infusion, with biosimilars priced 15%–30% lower.
- In the next five years, prices are projected to decline gradually, influenced by biosimilar adoption and market dynamics.
- Reimbursement policies favor biosimilars, which will further drive market share and reduce prices.
- Market growth remains robust driven by increasing cancer prevalence and expanding indications.
FAQs
Q1: How does patent expiry affect the price of NDC 45802-0102?
Patent expiry allows biosimilar development, leading to increased competition and price reductions for the original biologic.
Q2: What are the main drivers for biosimilar market penetration?
Regulatory approval pathways, cost containment policies, and payer incentives facilitate biosimilar adoption.
Q3: Will the price of this drug continue to decrease?
Yes, continued biosimilar entry and manufacturing efficiencies are expected to lower prices over the next five years.
Q4: How does the pricing of NDC 45802-0102 compare internationally?
Prices vary significantly; European markets often have lower prices due to negotiated discounts and different reimbursement models.
Q5: What factors could disrupt current price projections?
Regulatory delays, patent litigation, or changes in reimbursement policies could slow price decreases or cause price increases.
References
- IMS Health. (2022). Global Oncology Market Report.
- U.S. Food and Drug Administration. (2021). Guidance for Biosimilar Product Development.
- IQVIA. (2022). The Future of Biologics and Biosimilars.
- Centers for Medicare & Medicaid Services. (2022). Medicare Part B Drug Pricing Dashboard.
- PhRMA. (2023). Biopharmaceutical Industry Profile.
(Note: Specific product details, exact pricing, and projections are estimated based on market data trends for biologics with similar profiles.)
